BASF India Q1 FY27: consolidated PAT surges 162% YoY on Materials margin rebound
PAT +162.21% YoY · revenue +24.52% · margins expanding · beat vs street
₹4,824.26 Cr
+24.52% YoY
₹360.29 Cr
+162.21% YoY
7.43%
+3.9pp YoY
₹83.3
BASF India's Q1 FY27 (quarter ended June 30, 2026) consolidated profit for the period surged to ₹360.29 Cr, up 162.2% year-on-year from ₹137.40 Cr and up 423.1% sequentially from a weak ₹68.88 Cr in Q4 FY26. Stripping out the ₹18.15 Cr exceptional gain booked on the sale of BASF India Coatings, adjusted YoY PAT growth is still ~149.0%, confirming the beat is driven by core operations and not the one-off. Revenue from continuing operations (the statement now excludes the divested Coatings business) came in at ₹4,824.26 Cr, up 24.5% YoY over a base of ₹3,874.54 Cr that still included Coatings, and up 40.1% QoQ. Standalone PAT of ₹362.05 Cr is within 0.5% of the consolidated figure, so both bases tell the same story.
Q1 FY-2027 vs prior quarters
The expansion is margin-led: consolidated net margin rose to ~7.5% from 3.5% YoY and 2.0% QoQ, while segment operating margin improved to ~10.8% from 5.5% YoY and 3.2% QoQ. The swing is concentrated in two segments — Materials PBIT flipped from a ₹11.62 Cr loss in Q1 FY26 to a ₹212.69 Cr profit this quarter, and Chemicals PBIT rose to ₹96.12 Cr from ₹16.32 Cr — consistent with a recovery in petrochemical/monomer spreads rather than a volume story. That was partly offset by Agricultural Solutions, whose PBIT fell 53% YoY to ₹77.49 Cr from ₹165.39 Cr, and Nutrition & Care, down to ₹11.06 Cr from ₹20.23 Cr. Agricultural Solutions' QoQ swing (from a ₹19.83 Cr loss to a ₹77.49 Cr profit) is a known seasonal pattern the filing itself flags for that segment, so it should not be read as trend confirmation — the YoY decline is the more telling number.
The stock went into the print at ₹4,091.5, up 12.4% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; revenue is at a 6-quarter high.
Management highlighted a robust performance in the last quarter, driven by strong volume growth in Nutrition & Care and Industry Solutions, despite overall flat year-on-year sales due to price impacts and higher input costs. While specific forward-looking quantitative guidance is not provided, the company indicated con
— This quarter: beat
Against our pre-result preview, the print is a clear beat: the preview flagged revenue of ₹3,400-3,600 Cr, OPM of 12-14%, and PBT margin of 3-4% for the quarter — actual revenue of ₹4,824 Cr and PBT margin of ~10% both surpass those markers, though OPM at ~10.8% lands modestly below the previewed band. Q1 FY27 basic EPS of ₹83.3 alone is already ~98% of the ₹85.10 FY27 full-year consensus EPS the preview cited, implying either this run-rate isn't sustainable for the full year or consensus needs a material upward revision. Management's prior concall (May 2026) offered no quantitative guidance, only qualitative priorities — protecting margins, executing the Celesto and Dispersion Line 3 expansions, and completing the Coatings and Agricultural Solutions portfolio actions; margin protection was not just met but exceeded, though no company press release with management's own framing of this quarter could be extracted from this filing. On the portfolio actions: the Coatings stake sale (100%, ₹230.16 Cr consideration) completed June 30, 2026 and is booked as an exceptional item/discontinued operation this quarter; the Agricultural Solutions demerger cleared its shareholders' meeting on June 24, 2026 but remains subject to further regulatory approvals per the filing notes. Separately, the company disclosed a 14.18% stake acquisition in Clean Max Galapagos the same day as this result, a renewable-energy investment not reflected in this quarter's P&L.
W1
Whether the Materials/Chemicals margin recovery (PBIT swung to ₹212.69 Cr and ₹96.12 Cr this quarter from a loss/low a year ago) holds into Q2 FY27
W2
Final terms and completion timeline of the Agricultural Solutions demerger, approved by shareholders June 24, 2026 but still pending regulatory clearances
W3
Whether FY27 consensus EPS (~₹85.10 per the pre-result preview) gets revised given Q1 alone delivered ₹83.3 EPS
Informational and educational content only. Not investment advice.